Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.

@article{Zhang2013LenalidomideEI,
  title={Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.},
  author={L Zhang and Jolanta Kosek and Maria Axenovich Clifford Bergman Leslie Hogben Chong Wang and Carla Heise and Peter H. Schafer and Rajesh K. Chopra},
  journal={British journal of haematology},
  year={2013},
  volume={160 4},
  pages={487-502}
}
Durable responses with lenalidomide monotherapy have been reported in patients with non-Hodgkin lymphoma. In relapsed/refractory diffuse large B-cell lymphoma (DLBCL), higher responses were observed in the activated B-cell-like (ABC) subtype than in the germinal centre B-cell-like subtype. Herein, the molecular mechanisms involved in the differential efficacy of lenalidomide in DLBCL subtypes were investigated. Using DLBCL cell lines, lenalidomide treatment was found to preferentially suppress… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Novel targeted therapies in diffuse large B-cell lymphoma.

Seminars in hematology • 2015
View 6 Excerpts
Highly Influenced

Primary testicular lymphoma.

View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…